The medication is commonly used for the continuous, long-term management of persistent asthma in patients (12 years of age and older). It is applied in addressing conditions involving inflammatory or irritative processes of the airways. Its role is in the long-term management of asthma, used in situations involving recurrent or episodic manifestations where continuous preventative support may be part of symptomatic management. The therapeutic benefit is that it helps maintain a sense of stability when symptoms are more noticeable.

Альвеско plays a role in managing symptom clusters that may become intense or disruptive, such as frequent wheezing, persistent coughing, and feelings of chest tightness, especially those that interfere with daily comfort. This provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms. It is considered relevant when additional symptomatic support is needed for patients experiencing an increased need for a separate relief inhaler.

Quick Fact: Relief for Recurrent Wheezing Альвеско may assist with reducing the frequency and severity of symptoms associated with acute or episodic changes, supporting patients during difficult episodes.

Regulatory References

1. NIH MedlinePlus Drug Information

The eligibility for Альвеско (Ciclesonide) is strictly defined by regulatory authorities based on age, acute medical status, and pre-existing conditions.

Populations for Whom Use is Regulated

Category	Official Regulatory Statement
Approved Age Groups	Approved for adults and adolescents 12 years of age and older.
Pediatric Limitations	Safety and efficacy have not been established in children under 12 years of age (FDA). Use in children under 6 years is generally not recommended.
Contraindications	Use is strictly contraindicated for the primary treatment of status asthmaticus or other acute asthma episodes where intensive measures are required. Also contraindicated in patients with known hypersensitivity to the active ingredient or any excipients.
Use with Caution	Use requires caution in patients with active or quiescent tuberculosis or untreated systemic fungal, bacterial, viral, or parasitic infections. Patients with severe hepatic impairment should be closely monitored.

No dose adjustment is deemed necessary for elderly patients or individuals with renal impairment. During pregnancy, the medicine should only be used if the potential benefit to the mother justifies the potential risk, and the lowest effective dose should be maintained.

Interactions with other medicines and products

The interaction profile of Альвеско (Ciclesonide) is primarily defined by the metabolic pathway of its active metabolite, des-ciclesonide, as documented in government regulatory sources (e.g., FDA, EMA).

Documented Pharmacokinetic Interactions

Mechanism	Interacting Substances	Official Restriction
CYP3A4 Inhibition	Potent inhibitors like ketoconazole, ritonavir, itraconazole, or nelfinavir	Co-administration should be avoided unless benefit outweighs risk

The active metabolite is principally metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme. Co-administration with potent CYP3A4 inhibitors has been shown in regulatory studies to increase the systemic exposure (AUC) of the active metabolite by approximately 3.5-fold.

This significant increase in drug concentration requires a formal regulatory restriction: the combination with these potent inhibitors should be avoided due to the associated risk of increased systemic corticosteroid effects.

Population-Specific Considerations

• Severe Hepatic Impairment: Increased systemic exposure of the active metabolite is expected in patients with severe liver problems. Regulatory documents recommend that these patients be monitored for potential systemic effects, as clinical data for this population are limited.

Other Interactions

No mandatory dosing separation intervals, transporter-mediated interactions, or documented interactions with food, alcohol, or herbal products are explicitly stated in the official prescribing information.

How Альвеско Works — Mechanism of Action

---

Prodrug Activation and Targeted Glucocorticoid Receptor Agonism

The mechanism initiates upon inhalation, where the inactive parent drug, Ciclesonide, undergoes enzymatic hydrolysis to its high-affinity active metabolite, des-ciclesonide, via local esterase enzymes within the lung tissue. This localized activation strategy concentrates the active steroid, which then functions as a strong agonist (activator) of the intracellular Glucocorticoid Receptor ( GRalpha) . This targeted binding is the first molecular step that launches the anti-inflammatory cascade within the pulmonary epithelium.

---

Genomic Suppression of Chronic Inflammatory Cascades

Once activated, the GR complex modulates gene transcription by initiating a dual-action mechanism: Transrepression inhibits the activity of key pro-inflammatory transcription factors like NF-kappa B, thereby repressing the expression of genes that produce inflammatory mediators ( Cytokines). Simultaneously, Transactivation increases the expression of anti-inflammatory proteins, such as Lipocortin-1, which inhibits the synthesis of inflammatory mediators like Prostaglandins. This sequence of events regulates the activity of the underlying signaling pathways.

---

Physiological Consequence: Airway Structural Modulation

The overall effect of this specific genomic modulation is a reduction in cellular infiltration and tissue edema (swelling) within the bronchial lining. By consistently suppressing the chronic inflammatory response at its molecular source, the mechanism reduces excessive physiological reactivity and fluid accumulation. This physiological shift contributes to the prolonged pharmacological effect and structural regulation of the epithelial layer.

The administration of Alvesco, known generically as Ciclesonide, is restricted to the orally inhaled route using a pressurized metered-dose inhaler (MDI). It is designated exclusively for long-term daily maintenance of respiratory conditions and must not be used for the treatment of acute breathing difficulty.

---

Dosing and Frequency

The required dosing regimen is determined by the patient's current or previous therapy, with the goal of ultimately using the lowest effective dosage for stability. The medicine is administered once or twice daily, depending on the total required dose. For many adults and adolescents (aged 12 years and older), the starting dose is 80 mcg twice daily. The official maximum total daily dose for this population is 640 mcg, typically administered as 320 mcg twice daily. Any potential dose adjustment should be evaluated only after a minimum of four weeks of continuous therapy, as this duration is often required to achieve the full beneficial effect. If a dose is missed, the standard protocol is to skip the missed dose and take the next dose at its scheduled time, strictly avoiding the doubling of doses. The medicine is not indicated for use in children under 12 years of age.

---

Preparation and Post-Use Protocol

Proper administration requires specific procedural steps. If the inhaler is new or has been unused for 10 days or more, it must be primed by actuating it three times into the air. Critically, after each inhalation, the patient must rinse the mouth with water and spit out (without swallowing) to ensure correct usage.

Research Evidence / Overview of Studies for Альвеско

Research Exploring Application in Maintenance Treatment of Persistent Asthma

Research explored Альвеско (Ciclesonide) primarily in short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time in patients with persistent asthma. The main goal of these trials included monitoring outcomes related to systemic or functional imbalance, such as lung function measurements (like forced expiratory volume in 1 second, or FEV1), alongside patient-reported outcomes describing perceived discomfort and daily activity levels. The populations most frequently observed in this research included adults and adolescents aged 12 and older.

The findings from these short-term studies describe patterns observed over the course of the study period. This evidence contributes to the broader evidence landscape by providing insight into short-term changes in conditions characterized by fluctuating or episodic manifestations. It is important to note that most of this initial evidence comes from research exploring short-term symptom changes, meaning that follow-up durations were limited, and the evidence does not determine whether an individual will respond similarly over a much longer period of time.

Comparing Альвеско to Placebo and Other Treatments

When was studied for its application relative to placebo, findings show patterns related to measured changes in lung function and symptom control observed over the study intervals. The research describes that the measured outcomes related to physical discomfort and changes in lung function were observed in some studies to be in a similar range to those with the other active treatments.

Long-Term Research and Durability of Study Findings

The available evidence still shows patterns related to the fact that long-term effects are not fully established regarding the sustained impact on symptoms over several years. The impact on severe conditions associated with acute or disruptive episodes, such as the long-term rate of asthma exacerbations, remains uncharacterized in existing studies because trials with longer follow-up durations are less common.

Evidence in Special Populations

Research explored its application in various patient groups beyond the general adult population. Data for certain groups remain insufficient. The overall data are still emerging for some of the more complex patient subgroups, where sample sizes were modest or where comparative evidence is scarce. Research continues to evolve in these areas to provide further context.

Key Studies & References

1. Efficacy and safety of ciclesonide in adolescents and adults with asthma: A pooled analysis of three 12-week trials
2. Safety of Ciclesonide in Asthma: A Comprehensive Review

Common questions about Альвеско (FAQ)

Q: How is the active ingredient in Альвеско described differently from other inhaled steroids?

According to official information, the active ingredient (Ciclesonide) is described as an inactive prodrug that only becomes activated by enzymes once it reaches the lung tissue. This mechanism is designed to concentrate the anti-inflammatory effect in the lungs and minimize the amount of active drug that affects the rest of the body, which helps reduce the potential for systemic side effects.

Q: Can using Альвеско lead to a dry mouth or change in voice?

Yes, official safety data has reported dry mouth and hoarseness or voice changes (medically known as dysphonia) as adverse reactions in clinical trials. These effects are typically classified as uncommon or with an unknown frequency.

Q: Does the active ingredient in Альвеско only affect the lungs, or does it circulate throughout the whole body?

The medicine is designed for localized treatment within the lungs. Studies and regulatory documents report that the active substance has low oral absorption and is rapidly cleared from the body, meaning there is very little of the active drug that circulates, which is intended to reduce the potential for systemic side effects.

Q: Can pregnant women or those who are breastfeeding use Альвеско?

Official information advises that the medicine should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the developing baby. For breastfeeding, expert opinion generally considers inhaled corticosteroids acceptable because the amount of medication likely to be absorbed into the bloodstream and passed into breast milk is very small.

Q: Why is this medication given via inhalation instead of an oral pill?

The medicine is formulated for inhalation to utilize its unique prodrug mechanism and enable localized activation directly within the lung tissue. This method aims to maximize the anti-inflammatory effect at the target site while reducing systemic exposure throughout the rest of the body.

Q: Does long-term use of Альвеско carry a risk of affecting bone density?

Long-term use of inhaled corticosteroids may be associated with a risk of decreased bone mineral density. Regulatory documents include a warning that patients with major risk factors for low bone mass (e.g., family history of osteoporosis) may require monitoring for this potential risk.

Q: Are there reported interactions between Альвеско and common antifungal medicines?

Yes, official labeling includes warnings regarding certain drug interactions. Co-administration with potent inhibitors of the CYP3A4 enzyme, such as specific antifungal medicines (e.g., ketoconazole or ritonavir), is listed as a combination to be avoided unless the benefit is considered to outweigh the risk, due to the potential for increased drug exposure.

Q: Does the time of day a patient uses Альвеско make a difference?

Regulatory information indicates the medicine is typically administered once or twice a day and notes that patients are generally instructed to use it at around the same times every day for consistent asthma management.

Q: Is there a risk of weight gain when using Альвеско for a long period of time?

Weight gain, sometimes characterized by fat deposits around the face, neck, and trunk, has been observed rarely in patients using this type of medication, according to clinical safety data.

Q: Is Альвеско used to treat any other conditions besides asthma, such as COPD?

Official regulatory approval for this medicine is specifically for the long-term maintenance treatment of asthma in adults and adolescents aged 12 years and older.

Q: What happens if a person suddenly stops using Альвеско?

Official guidance states that treatment is typically tapered off gradually under professional supervision, and abrupt discontinuation is not recommended. Abrupt withdrawal may be associated with unpleasant symptoms or, rarely, other serious conditions, particularly when transitioning from previous systemic (oral) steroid therapy.

Q: Does Альвеско contain any common allergens or ingredients like lactose?

The medicine is a metered-dose inhaler (MDI) solution that uses hydrofluoroalkane-134a (HFA) as its propellant. The official label confirms the primary inactive ingredients and does not list lactose, which is not commonly used in MDI formulations, as an excipient.

Q: What are the symptoms that indicate a patient should contact their prescriber about Альвеско not working?

Official prescribing information states that contact with a healthcare provider is warranted if a patient's asthma worsens or if they feel the medication is making their condition worse during treatment.

Q: Is it necessary to use a spacer device with the Альвеско inhaler?

The official product label does not mandate the use of a spacer device. However, a spacer is often noted as a beneficial tool by healthcare professionals to help ensure the medicine is properly delivered to the lungs.

Q: What is the main component of the propellant used in the Альвеско inhaler?

The medicine is administered using a metered-dose inhaler that uses hydrofluoroalkane-134a (HFA) as its propellant.

Q: Can a person with diabetes use Альвеско, and are there special concerns?

As a glucocorticoid, this medicine may have potential systemic metabolic effects on blood sugar levels. Regulatory authorities include a warning that patients with pre-existing diabetes may require monitoring for potential worsening of glycemic control, due to the medicine's class.

Q: Why do people sometimes stop using Альвеско?

While the decision to discontinue is clinical, official documents imply that stopping may be related to managing adverse reactions, achieving long-term asthma control, or the process of tapering off the medicine when transitioning from previous systemic steroid therapy.

Alvesco (ciclesonide) must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The product must be protected from freezing, direct light, and excessive heat. Do not expose the pressurized canister to temperatures above 49 C (120 F), as this may cause it to burst, according to official labeling. .

• The inhaler must be kept out of the sight and reach of children.
• Disposal is required when the dose counter reaches zero or the expiration date passes.
• The pressurized canister must not be punctured or thrown into a fire or incinerator, even when empty.
• Dispose of all unused product and waste material according to local regulations.